99% High Assay NSI-189 1270138-40-3 API Raw Pharmaceutical Materials

Pharmaceutical Raw Materials NSI-189 1270138-40-3 API Manufacturer Made In China

Product Name: (4-benzylpiperazin-1-yl) - [2 - (3-methylbutylamino) pyridin-3-yl] methanone

Other names: (4-benzyl-1-piperazinyl) {2 - [(3-methylbutyl) amino] - 3-pyridinyl} methanone

Methanone, [2-[(3-methylbutyl)amino]-3-pyridinyl][4-(phenylmethyl)-1-piperazinyl]-

unii-yve9u408zl

Density: 1.134 ± 0.06 g / cm3 (20 ° C 760 Torr),

Solubility: almost insoluble (0.07 g / L) (25 ° C)

Storage conditions: powder - 20 ° C 3 years

NSI-189 review articles show that NSI-189 is a drug under trial by a US-based Biotechnology Company called Neuralstem Inc. The drug has been under development for years. The first trials were commenced over seven years ago. At first, NSI 189 was seen as a promising treatment for MDD but so far clinical trials have not proven this. However, there is the potential for NSI 189 to be explored as a Nootropic.

Clinical trials done on patients show that test subjects involved in the trials were able to report significant memory improvements. Whether this is the way the manufacturer wishes to go remains to be seen. But when you consider the setbacks in studying the drug for MDD, exploring it as a possible treatment for memory loss and other cognitive impairments could be the next course of action.